Privately-held NeoRx Corp said it hasentered into an exclusive agreement with Genentech Inc for thedevelopment of an injectable diagnostic to image blood clots.    It said it Genentech will be responsible for marketing, andNeoRx will receive royalties based on sales.  The product willuse a proprietary NeoRx method of attaching the radioisotopetechnetium-99m to Genentech's blood clot dissolving drug tissueplasminogen activator, or Activase. Reuter&#3;